Noticias y Actividades de Fractyl Laboratories

Ver el organigrama con sus 23 ejecutivos principales

Biografías más buscadas en Fractyl Laboratories

• Harith Rajagopalan, Chief Executive Officer and Director
• Kelly Barnes, Director
• Marc Elia, Director

Recientes movimientos de ejecutivos en Fractyl Laboratories

• Jonathan Labinger, se ha incorporado a la empresa como Payable Accountant  (noticia publicada el 20 de mayo de 2025).

Crear su alerta
para seguir los movimientos de los ejecutivos en Fractyl Laboratories.

Fractyl Laboratories tiene 2.350 competidores entre los que se incluyen Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) y Lonza (Suiza).

Popular M&A news in Biotecnología

• Sirius Therapeutics acaba de anunciar una recaudación de fondos de 50 millones de dólares. (publicado el 16 de junio de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado el 12 de junio de 2025).
• SpliceBio acaba de anunciar una recaudación de fondos de 135 millones de dólares. (publicado el 11 de junio de 2025).

Otros contactos sugeridos en el sector Biotecnología

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships en WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board en Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization en Wheeler Bio

Saber más sobre el sector Biotecnología

Últimos comunicados de prensa de Fractyl Laboratories

• Fractyl Health Announces Increased Focus on Groundbreaking Revita® Weight Maintenance and Rejuva® Pancreatic Gene Therapy Programs with Potential to Deliver Key Clinical Milestones Across Multiple Studies in 2025 | Fractyl Health, Inc.
• Fractyl Health Announces Positive Initial Clinical Results Demonstrating Weight Maintenance Following GLP-1 Discontinuation and Revita Procedure in First Patient of the REVEAL-1 Cohort | Fractyl Health, Inc.
• Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | Fractyl Health, Inc.
• Fractyl Health Unveils Promising Preclinical Data Demonstrating Safety and Feasibility of Local Delivery of RJVA-001 Rejuva® Smart GLP-1™ Pancreatic Gene Therapy at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC) | Frac
• Fractyl Health to Participate in the Upcoming December Conferences | Fractyl Health, Inc.
• Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates | Fractyl Health, Inc.
• Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024 | Fractyl Health, Inc.
• Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024 | Fractyl Health, Inc.
• News Releases | Fractyl Health, Inc.
• Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024 | Fractyl Health, Inc.
• View more press releases Close

Redes sociales sobre Fractyl Laboratories

• Fractyl Laboratories en Wikipedia, Google News y Yahoo Finance
• Fractyl Laboratories en LinkedIn, Twitter y YouTube